Key result
RAAS pathway genes AGT and RENBP are strongly linked to the risk of renal events.
Why the study?
Do renin-angiotensin-aldosterone system (RAAS) gene variants associate with chronic kidney disease progression?
Cohort (n=3,013)
Do renin-angiotensin-aldosterone system (RAAS) gene variants associate with chronic kidney disease progression?
p-value: p=< 1.00 × 10(-6)
Genetic variations in the RAAS pathway, specifically in the AGT and RENBP genes, are strongly associated with the progression of chronic kidney disease.
Gene-level RAAS associations with CKD events require replication; leaves open clinical utility for risk prediction or targeted therapy.
BACKGROUND: We conducted single-marker, gene- and pathway-based analyses to examine the association between renin-angiotensin-aldosterone system (RAAS) variants and chronic kidney disease (CKD) progression among Chronic Renal Insufficiency Cohort study participants. METHODS: A total of 1523 white and 1490 black subjects were genotyped for 490 single nucleotide polymorphisms (SNPs) in 12 RAAS genes as part of the ITMAT-Broad-CARe array. CKD progression phenotypes included decline in estimated glomerular filtration rate (eGFR) over time and the occurrence of a renal disease event, defined as incident end-stage renal disease or halving of eGFR from baseline. Mixed-effects models were used to examine SNP associations with eGFR decline, while Cox proportional hazards models tested SNP associations with renal events. Gene- and pathway-based analyses were conducted using the truncated product method. All analyses were stratified by race, and a Bonferroni correction was applied to adjust for multiple testing. RESULTS: Among white and black participants, eGFR declined an average of 1.2 and 2.3 mL/min/1.73 m(2)/year, respectively, while renal events occurred in a respective 11.5 and 24.9% of participants. We identified strong gene- and pathway-based associations with CKD progression. The AGT and RENBP genes were consistently associated with risk of renal events in separate analyses of white and black participants (both P < 1.00 × 10(-6)). Driven by the significant gene-based findings, the entire RAAS pathway was also associated with renal events in both groups (both P < 1.00 × 10(-6)). No single-marker associations with CKD progression were observed. CONCLUSIONS: The current study provides strong evidence for a role of the RAAS in CKD progression.
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2015) conducted a cohort in Chronic kidney disease (CKD) (n=3,013). Renin-angiotensin-aldosterone system (RAAS) genetic variants was evaluated on Decline in estimated glomerular filtration rate (eGFR) over time and the occurrence of a renal disease event (incident end-stage renal disease or halving of eGFR from baseline) (p=< 1.00 × 10(-6)). The AGT and RENBP genes, as well as the entire RAAS pathway, were significantly associated with the risk of renal events in both white and black participants (P < 1.00 × 10(-6)).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: